T-ANGIOVASC - Targeting of angiogenic tgf-b signalling in cancer and cardiovascular diseases (LIFE QUALITY) (2001-09-01 - 2005-06-30) (»add to infobox)

Christos MASSALAS, Rudy DE KEYSER, Christian BRECHOT, Anton BERNS, Ronald PLASTERK, Digby HARRIS

UNIVERSITY OF IOANNINA (GR213 - Ioannina) (Greece), FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY (BE242 - Arr. Leuven) (Belgium), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR714 - Isère) (France), NETHERLANDS CANCER INSTITUTE/ANTONI VAN LEEUWENHOEK HOSPITAL (NL326 - Groot-Amsterdam) (Netherlands), NETHERLANDS INSTITUTE FOR DEVELOPMENTAL BIOLOGY (NL310 - Utrecht) (Netherlands), UNIVERSITY OF NEWCASTLE UPON TYNE (UK132 - Tyne And Wear) (Great Britain)

Diseases as common as cancer, diabetes associated blindness and coronary arteriosclerosis, and as rare as hereditary hemorrhagic telangiecstasia (HHT), a chronic, bleeding ailment, would benefit from exogenous control of angiogenesis. Gene ablation in mice has shown that the transforming growth factor (TGF) beta signal transduction pathway is essential for normal vasculogenesis and angiogenesis while mutations in TGF beta-receptors cause HHT. Treatments of vascular disease based on interference with local ligand concentrations are not feasible because of side effects on the immune system and fibrosis. Here, we will use state-of-the-art technology to identify target genes downstream of activated receptors in vascular cells and develop cell culture and animal models for vascular disease associated with defective TGF beta signalling.

PERSONS (6/6)

RELATED NAVIGATION AREA(S) (2/2)